Oruka Therapeutics (ORKA) Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ORKA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Oruka Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$107.40 |
| 52 Week High | US$109.42 |
| 52 Week Low | US$14.03 |
| Beta | 0 |
| 1 Month Change | 27.01% |
| 3 Month Change | 68.08% |
| 1 Year Change | 600.59% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 272.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| ORKA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.5% | 4.5% | 1.0% |
| 1Y | 600.6% | 38.3% | 18.4% |
Return vs Industry: ORKA exceeded the US Biotechs industry which returned 41.3% over the past year.
Return vs Market: ORKA exceeded the US Market which returned 19% over the past year.
Price Volatility
| ORKA volatility | |
|---|---|
| ORKA Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ORKA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ORKA's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 68 | Lawrence Klein | orukatx.com |
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001.
Oruka Therapeutics, Inc. Fundamentals Summary
| ORKA fundamental statistics | |
|---|---|
| Market cap | US$6.93b |
| Earnings (TTM) | -US$109.69m |
| Revenue (TTM) | n/a |
Is ORKA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORKA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$109.69m |
| Earnings | -US$109.69m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.66 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ORKA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/12 07:24 |
| End of Day Share Price | 2026/08/12 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oruka Therapeutics, Inc. is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | Barclays |
| Julian Harrison | BTIG |
| Yatin Suneja | Guggenheim Securities, LLC |